Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter J. Wyld"'
Autor:
Peter J. Wyld, Paul Rolan, Kelvin R. Palmer, Irving S. Benjamin, Peter M. Lloyd, F. Mullins, Felix Waldmeier, Gerard Flesch, Laurence J. Brookman, Antoine Sioufi
Publikováno v:
Clinical Pharmacology & Therapeutics. 62:272-278
Objectives Valsartan (CGP 48933), an orally active angiotensin II antagonist, is eliminated mainly by hepatic clearance. To characterize the compound(s) excreted in the bile, biliary excretion of valsartan was investigated by collection of bile after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c08e72eb96043fa96de43bc7efe6f6
https://doi.org/10.1016/s0009-9236(97)90029-1
https://doi.org/10.1016/s0009-9236(97)90029-1
Autor:
Peter J. Wyld
Publikováno v:
Journal of the Royal Society of Medicine. 76(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0845adefadd9f4fba321fd574be19bfc
https://pubmed.ncbi.nlm.nih.gov/20894479
https://pubmed.ncbi.nlm.nih.gov/20894479
Autor:
Anna Pluzanska, Peter J. Wyld, Magdolna Dank, Raquel Lang, Dominique Becquart, Robert S. Smith, Ramon Perez-Carrion, Poonamalle P. Bapsy, Eeva Salminen, Corrado Boni, Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun, H. A. Chaudri-Ross, Fritz Jaenicke, Harm Sleeboom, Justus Apffelstaedt, Alain Monnier, Ajay Bhatnagar, Raymond Snyder
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(11)
Purpose: To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer. Patients and Methods: This multicenter phase III trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34dce635009b5b10ef798601b918e68f
https://pubmed.ncbi.nlm.nih.gov/15284276
https://pubmed.ncbi.nlm.nih.gov/15284276
Autor:
Marie-Edith Anne Bonneterre, Austin James Combest, Ashley Erickson Simmons, Paulina Zelenay McAtee, J. Balkissoon, Peter J. Wyld, Angelena Moseley, Dirk J. Reitsma
Publikováno v:
Journal of Clinical Oncology. 32:e12526-e12526
e12526 Background: HER2 targeting in gastric cancer (GC) is a relatively new approach. The ToGA trial demonstrated the importance of HER2 over-expression in GC. Unlike breast cancer, little informa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::698daa5fc98849760aa31bc4c3644f3c
https://doi.org/10.1200/jco.2014.32.15_suppl.e12526
https://doi.org/10.1200/jco.2014.32.15_suppl.e12526
Autor:
Katherine M. Cooper, Jean L. Simmons, Lester I. Harrison, Peter J. Wyld, Bruce P. Ekholm, David Donnell
Publikováno v:
The Journal of pharmacy and pharmacology. 48(6)
A 28-day double-blind parallel group study has been conducted to compare the safety and tolerability of HFA-134a, a chlorofluorocarbon-free propellant in a pressurized metered-dose inhaler (MDI A), with a chlorofluorocarbon propellant (MDI C). Sixtee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea945a322eaf3509660fe717138aa283
https://pubmed.ncbi.nlm.nih.gov/8832493
https://pubmed.ncbi.nlm.nih.gov/8832493
Autor:
Quentin Campbell-Hewson, Darren Hargrave, Victoria Lock, John Lyons, Peter J. Wyld, Sarah Halford, Alan V. Boddy, Murray Yule, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Guy Makin, Lucas Moreno
Publikováno v:
Journal of Clinical Oncology. 30:9542-9542
9542 Background: AT9283, is a multi-targeted inhibitor, against Aurora A and B, JAK & ABL kinases. Aurora kinases are potential therapeutic targets in paediatric solid cancers. Methods: A phase I dose escalation study was performed using a 72 hour in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57c4fdc0edc07b63bcc90b43518d6e98
https://doi.org/10.1200/jco.2012.30.15_suppl.9542
https://doi.org/10.1200/jco.2012.30.15_suppl.9542
Publikováno v:
Cancer. 54:48-53
Two patients fulfilled the clinical and hematologic criteria for B-cell acute lymphoblastic leukemia: the malignant cells had L3 morphology, bore B-cell markers, and carried the specific t(8;14) translocation. The leukemic cells of one patient were t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93dc060e079d3ef6a2ce3ac15708baec
https://doi.org/10.1002/1097-0142(19840701)54:1<48::aid-cncr2820540112>3.0.co
https://doi.org/10.1002/1097-0142(19840701)54:1<48::aid-cncr2820540112>3.0.co
